Unknown

Dataset Information

Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report.


ABSTRACT:

Rationale

Limited patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) have achieved complete response (CR) from induction chemotherapy (IC). Neoadjuvant immunotherapy combined with chemotherapy has marked therapeutic effects in some locoregionally advanced solid tumors. However, its efficacy and safety of NPC have not been reported so far. The rapid response of neoadjuvant tislelizumab combined with chemotherapy on LA-NPC may be associated with long-term survival benefit.

Patient concerns

A 57-year-old male patient presented with a 2-month history of bloody nasal discharge and right neck mass for 2 weeks.

Diagnosis

The patient was eventually diagnosed with nasopharyngeal nonkeratinizing undifferentiated cell carcinoma (stage IVA).

Interventions<

SUBMITTER: Tang H 

PROVIDER: S-EPMC9936014 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature